ACTRN12624000322538招募中1 期
A Phase 1b/2a Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate Efficacy, Safety, Tolerability and the Pharmacokinetics of GL0034 (Utreglutide) in the Treatment of Non-alcoholic Fatty Liver Disease
International Sponsor: Sun Pharmaceutical Industries Ltd0 个研究点目标入组 48 人开始时间: 2024年3月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1) Male or female aged 18 to 70, inclusive at the time of Screen 1.
- •2) Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol, prior to any study procedures at Screen 1.
- •3) BMI greater than or equal to 30.0 kg/m2 with weight not exceeding the maximum capacity of the local MRI machine or facility infrastructure as per standard practices inclusive at the time of Screen 1, Screen 2, and Day 1.
- •4) Controlled attenuated parameter (CAP) greater than or equal to 306 dB/m via fasting FibroScan® assessment at Screen 1.
- •5) Liver fat content greater than or equal to 10%, as assessed by MRI-PDFF at Screen 2
排除标准
- •1) History or previous diagnosis of, or currently experiencing any medical condition that may increase the risk associated with study participation, limit the participants ability to complete the study, or to comply with protocol requirements, or to absorb the IP, or interfere with the interpretation of study results, including:
- •-Non-NAFLD chronic liver disease.
- •-Proliferative retinopathy or maculopathy requiring acute treatment
- •-Current diagnosis of a mental health disorder, as defined by DSM-5 with active suicidal ideation.
- •- Previous clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions.
- •-Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, or manifest hypo- or hyperthyroidism.
- •- Pancreatitis (acute or chronic).
- •-Any other clinically significant unstable medical condition, or laboratory abnormality which, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- •Note: Participants with diet-controlled type-2 diabetes (T2D) who have an HbA1c less than or equal to 8 are permitted in this study.
- •2) Participants with clinically relevant laboratory abnormalities, as assessed by local laboratory, that in the investigator’s opinion could impact participant safety.
- •3) History of regular and excessive alcohol consumption exceeding 14 standard drinks/week for female participants or 21 drinks/week for male participants (1 drink is equivalent to 150 mL of wine, 360 mL of beer or 45 mL liquor) within the previous 6 months of informed consent.
- •4) Evidence or previous diagnosis of the following infections:
- •-Hepatitis B virus,
- •-Hepatitis C virus (HCV)
- •-Human immunodeficiency virus (HIV)
- •-Acute (current and active) Coronavirus disease 2019 (COVID-19) infection.
- •5) Unstable or poorly controlled hypertension that in the investigator’s opinion would impact participant safety.
- •6) Supine 12-lead ECG (average) demonstrating a QTcF interval greater than 450 msec or a QRS interval greater than 120 msec, that in the investigator’s opinion could impact participant safety.
- •7) Estimated GFR <60 mL/min/1.73m2
- •8) Participants meeting criteria for contraindication for MRI, including:
- •-History of severe claustrophobia impacting ability to perform MRI during the study.
- •-Current implants, devices, objects, or markings within or on the body, containing metal or material not compatible with MRI.
- •-Unable to lie still or maintain a breath hold for the required period to acquire MRI images (15 to 20 seconds).
- •-Abdominal girth or weight exceeding the maximum capacity of the local MRI system.
- •9) Participants taking any prohibited concomitant medication(s) or those unable to switch to permitted concomitant medication(s)
- •-Systemic treatment with vitamin E in the period from 90 days prior to Screen 2 (topical use is allowed).
- •- Treatment with drugs with a potential effect on steatosis; corticosteroids (topical and inhaled are allowed), methotrexate, tamoxifen, valproic acid, amiodarone or tetracycline in the period from 28 days prior to Screen 2.
- •- Treatment with orlistat, zonisamide, topiramate, phentermine, lorcaserin, bupropion and naltrexone alone or in combination, or any other medication that could promote weight loss in the opinion of the investigator in the period from 28 days prior to Screen 2.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to investigate the safety and effect of a drug called B-701 given with another drug Docetaxel on certain typesof bladder cancer that do not respond to treatment with standard therapy.EUCTR2017-001319-36-CZBioClin Therapeutics, Inc.261
进行中（未招募）
1 期
Clinical trial to investigate the safety and effect of a drug called B-701 given with another drug Docetaxel on certain types of bladder cancer that do not respond to treatment with standard therapy.EUCTR2017-001319-36-ESBioClin Therapeutics, Inc.261
进行中（未招募）
1 期
A clinical study to test the safety of CDNF by brain infusion in patients with Parkinson's disease.Idiopathic Parkinson's DiseaseMedDRA version: 21.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 100000004852EUCTR2015-004175-73-FIHerantis Pharma Plc17
进行中（未招募）
1 期
A Phase 2a clinical study to assess the safety, immunogeniocity, and efficacy of a MVA-BN-RSV Vaccine against viral respiratory infection in a challenge setting in healthy volunteers.EUCTR2017-004582-27-BEBavarian Nordic A/S72
进行中（未招募）
1 期
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b when added to standard of care anticoagulation therapy in Subjects With Acute Submassive Pulmonary EmbolismDS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE)MedDRA version: 20.0 Level: HLT Classification code 10037379 Term: Pulmonary embolism and thrombosis System Organ Class: 100000004866MedDRA version: 20.0 Level: PT Classification code 10037377 Term: Pulmonary embolism System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-005211-32-NLDaiichi Sankyo, Inc.116